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Pro-inﬂammatory cytokinesThe role of hepatitis C virus (HCV) in the pathogenesis of atherosclerosis and cardiovascular events is unclear.
The aim of this study was to evaluate the direct effect of HCV on cardiovascular risk and correlate it with pro
and anti-inﬂammatory cytokines in patients with HCV. HCV monoinfected patients, genotype 1, naive,
non-obese (BMIb30) and non-diabetics were included and compared to controls (blood donors). Patients
with prior diagnosis of cardiovascular diseases, hypertension, chronic renal failure, cancer and chronic use of
lipid-lowering drugs or immunosuppressants were excluded. Age, BMI, systolic blood pressure (SBP) and
diastolic (DBP), fasting glucose and lipid levels were determined. Serum cytokines (IL-6, IL-10 and TNF-α) and
Framingham score were also evaluated. 62 HCV patients, 34 (54.8%) were males and none of them was
smoking. The Framingham scores (median and 25th and 75th percentiles) were 12% (6.5–14%), showing an
intermediate cardiovascular risk in patients with HCV. There was signiﬁcant direct correlation between
Framingham and total cholesterol (p=0.043) and DBP (p=0.007). HDL-C (p=0.002) was inversely
correlated with the Framingham score. HCV patients had higher levels of proinﬂammatory cytokines (IL-6 and
TNF-α) compared to controls (pb0.0001) and the relation of proinﬂammatory/anti-inﬂammatory TNF-α/IL10
and IL-6/IL10 were higher in HCV patients (pb0.01). The Framingham score was directly correlated to IL-6
and TNF-α, but differences were not statistically signiﬁcant. Patients with HCVmonoinfected, nonobese, naïve
and non diabetic have an intermediate cardiovascular risk, as measured by the Framingham score and high
levels of proinﬂammatory cytokines (IL-6 and TNF).LT, alanine aminotransferase;
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Hepatitis C virus (HCV) infects about 2–3% of the world population
[1] and approximately 4 million of Americans are estimated to have
been infected with HCV [2]. HCV infection leads to chronic hepatitis in
up to 60–80% of infected individuals and is associated with liver
steatosis, ﬁbrosis and, insulin resistance (IR) [3–6].
Furthermore, some studies have been demonstrated an association
between infectious diseases such as Chlamydia, Helicobacter pyloriand also HCV and coronary atherosclerosis and carotid artery plaque
[7–11]. HCV infection is recognized to cause chronic immune
stimulation, leading to an inﬂammatory response and cytokine
production [12,13]. Two distinct patterns of cytokines production
may occur. Type 1 responses are characterized by production of IL-2,
TNF-α and IFN-γ, which prime and maintain antigen-speciﬁc cellular
immunity and are important in defense against viruses. Type 2
responses are characterized by IL-4, IL-5, IL6- and IL-10, which
promote humoral immune responses [14]. These altered cytokine
proﬁles observed in the setting of chronic HCV could potentially lead
to adverse cardiovascular outcomes. Thus, HCV induces inﬂammatory
cytokines, with consequent increase in intracellular adhesion mole-
cules, expression of anti-endothelium antibodies and generation of
oxidative stress, produces IR, interferes with the lipidmetabolism, and
is associated to Diabetes mellitus type 2 (DM) and systemic vasculitis.
Due to the above-mentioned reasons, it is easy to suppose that HCV
would be able to increase the cardiovascular risk [10].
Nevertheless, HCV is associated with a favourable lipid proﬁle,
with lower cholesterol and LDL levels [15]. A retrospective evaluation
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with chronic hepatitis C infection had signiﬁcantly lower levels of LDL,
cholesterol and triglycerides when compared to those who had never
been infected with hepatitis C [16,17]. This hypolipidemia resolves
with successful hepatitis C treatment but persists in nonresponders
[18]. Thus, it is unknown how infection with HCV affects coronary
heart disease (CHD) risk, progression and outcomes [19].
Based on these prior ﬁndings, the aim of this study was to evaluate
the direct effect of HCV on cardiovascular risk and correlate it with
serum concentrations of pro and anti-inﬂammatory cytokines in
patients with HCV.2. Patients and methods
2.1. Population
HCV monoinfected patients, naive, non-obese [Body mass index (BMI) below 30],
with no clinical signs of cirrhosis, non-diabetic, aged between 18 and 60 years, from
outpatient clinic of Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil and Liver
Institute of Pernambuco, Recife, Brazil, were included and compared to controls. This
HCV group consisted of 62 subjects deﬁned as documented positive HCV antibody and
detectable HCV RNA, all of them submitted to liver biopsy. Those with human
immunodeﬁciency virus and/or hepatitis B coinfection, hemochromatosis or recipients
of solid organ transplants were excluded. Subjects with clinical evidence of cirrhosis,
determined by the presence of portal hypertension, deﬁned by esophageal or gastric
varices on endoscopy, ascites or splenomegaly or evidence of synthetic dysfunction on
laboratory evaluation were also excluded. The controls were consecutive blood donors
from the Blood Bank of the Clinic Hospital of University of São Paulo non-infected with
HCV or other viruses, without metabolic syndrome factors (dyslipidemia, DM, high
blood pressure, central obesity), and with an IMC under 30. They had their clinical and
biochemical parameters registered.
Age, BMI, systolic blood pressure (SBP) and diastolic (DBP), fasting glucose and
lipid levels were determined. Identiﬁcation of type 2 DM, hypertension and
dyslipidemia followed the recommendations of the American Diabetes Association
[20].
Patients with prior diagnosis of cardiovascular diseases, systemic blood hyperten-
sion, chronic renal failure, cancer, alcohol abuse, pregnancy and chronic use of
lipid-lowering drugs or immunosuppressants were excluded.2.2. Laboratory evaluation and serum cytokine measurement
The laboratory evaluation in all patients included a blood cell count and the
measurement of aspartate aminotransferase (AST), alanine aminotransferase (ALT),
g-glutamyltranspeptidase, total cholesterol and fractions, triglycerides, fasting glucose,
and insulin levels. These parameters were measured using the standard techniques of
clinical chemistry laboratories (Modular P800, Hitachi, Roche Applied Science,
Indianapolis, IN, USA). IR was measured by the HOMA-IR index – the product of
fasting plasma insulin concentration (mIU/L) and fasting serum glucose (mg/dL)
divided by 405.
For the cytokine and chemokine measurements, the serum was stored at −80 C
until use. The serum cytokine levels (TNF-α, IL-6, and IL-10) were then measured using
a sensitive sandwich enzyme-linked immunosorbent assay (ELISA) kit (R&D System
Inc., Minneapolis, MN). All measurements were made in duplicate, and the average
values were used in the statistical analyses.Table 1
Demographic and clinical characteristics of the studied population.
Variable HCV (n=62)
Age mean±SD 52.94±8.55
Sex % male/female 54.8/45.2
BMIN30 0
Tobacco 0
Diabetes mellitus 0
Fibrosis – METAVIR n (%) F1 8 (12.9)
F2 37 (59.7)
F3 10 (16.1)
F4 7 (11.3)
Total cholesterol mg/dL mean±SD 152.26±26.8
HDL cholesterol mg/dL mean±SD 49.6±15.9
FRS 10 yr median (25–75th percentiles) 12 (6.5–14)
HOMA-IR median (25–75th percentiles) 1.94 (1.51–3.48)
Where: HCV=hepatitis C virus; SD=standard-deviation; NS=non-signiﬁcative; ND=non
Model Assessment For Insulin Resistance.2.3. Framingham Risk Scoring System (FRS)
The 10-yr likelihood for development of cardiovascular events was estimated for
each subject using the multivariate scoring system of the Framingham Heart Study
[21,22]. It calculates the risk from age, sex, systolic blood pressure, the ratio of total to
high-density lipoprotein (HDL) cholesterol, smoking habit, and presence of diabetes in
subjects between the ages of 45 and 75 yr. Patients at risk to undergo myocardial
infarction within the next 10 yr, according to the FRS were stratiﬁed into low (10%),
intermediate (10–20%), and high ( 20%) midterm risk groups.
3. Histological analysis
The liver tissue was ﬁxed in 4% formaldehyde and processed for
hematoxylin–eosin and Masson trichrome stains for histological
analysis. Histological analyses were evaluated by pathologist who
was unaware of the HCV genotype as well as the patient's clinical
characteristics. Stages of ﬁbrosis and grades of inﬂammation were
scored according to METAVIR, that it consists of F0 (no ﬁbrosis), F1
(portal ﬁbrosis without septa), F2 (portal ﬁbrosis with few septa), F3
(numerous septa without cirrhosis), F4 (cirrhosis). Steatosis was
graded 0–3 based on percentages of hepatocytes harbouring lipid
droplets in the biopsy (0 reﬂecting none; 1 equalling 0–33%; 2
referring to 33–66%; and 3 representing N66% steatotic hepatocytes).
3.1. Ethical consent
Speciﬁc informed consent was obtained for the study and the
protocol was approved by the Internal Review Board of the
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil,
Liver Institute of Pernambuco, Recife, Brazil, and University of São
Paulo, São Paulo, Brazil. The study was conducted in conformance
with the Helsinki Declaration. All patients gave written informed
consent.
3.2. Statistical analysis
Student's t test andWilcoxon test were used according to normality
assessment (Kolmogorov–Smirnov). By the same token, linear regres-
sion analysis (Pearson or Spearman correlation) was selected as
appropriate, complemented with logistic regression for qualitative
variables (gender and diagnosis). SPSS for Windows, version 10.0
(Chicago, IL, 148 USA) was employed. p values of less than 0.05 were
considered signiﬁcant.
4. Results
Demographic and clinical features of the subjects (n=62) and
control are listed in Table 1. 62 patients HCV, 28 (45.2%) were female
and 34 (54.8%) males were evaluated. None of them was smoking. TheControls (n=11) P
51.2±9.31 NS
53.4/46.7 NS
0 NS
0 NS
0 NS
ND NA
ND NA
ND NA
ND NA
ND NA
-determined; NA=not applied; FRS=Framingham risk score; HOMA-IR- Homeostasis
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(6.5–14%), showing an intermediate cardiovascular risk in patientswith
HCV. There was signiﬁcant direct correlation as evaluated by the
Spearman test between Framingham and total cholesterol (p=0.043)
and DBP (p=0.007). HDL-C (p=− 0.002) was inversely correlated
with the Framingham score. HCV patients had higher levels of
proinﬂammatory cytokines (IL-6 and TNF-α) compared to controls –
Figs. 1 and 2, but therewas no difference between the groups regarding
IL-10. The Framingham score was directly correlated to IL-6 (Spearman
rho=0.120) and TNF-α (Spearman rho=0.306), and inversely to IL-10
(Spearman rho=−0.013), but differences were not statistically
signiﬁcant. The relation of proinﬂammatory/anti-inﬂammatory
TNF-α/IL10 and IL-6/IL10 were higher in HCV patients (pb0.01) –
Fig. 3. There was no correlation among IR and Framingham score or
cytokine proﬁle.
5. Discussion
Currently, cardiovascular risk in HCV patients has been an
interesting focus, and the relationship between cardiovascular risk,
lipids, cytokines and atherosclerosis in these patients is not
completely elucided. In the present study, we demonstrated that
monoinfected, non-obese, non diabetic and non-clinically cirrhotic
HCV patients, have an intermediate cardiovascular risk, as measured
by the Framingham score (FRS) and high levels of proinﬂammatory
cytokines (IL-6 and TNF).
Cytokines play an important role in the defense against viral
infections, both indirectly, through determination of the predominant
pattern of host response, and directly, through inhibition of viral
replication. However, in the context of an inﬂammatory response
against a virus, cytokines may also lead to liver damage.
There are some recently published studies focusing on cardiovas-
cular disease during chronic HCV infection. Two of them are
particularly interesting, and deserve some comments. In the ﬁrst
one, the Heart and Soul Study [23], a cohort of more than 900 patients
with cardiovascular disease was evaluated – 8.6% of them HCV
positive. Those infected with the virus have higher TNFα as well as
higher risk of cardiac failure and death. The second, a study fromControl
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Fig. 1. Levels of TNF-α in controls andEgypt [24], with a large number of patients, has demonstrated that
patients infected with HCV has higher intima-media thickness than
controls. However, we consider that the main issue is to verify the
relationship between HCV and cardiovascular risk, not cardiovascular
disease, as the ﬁrst is more prone to be able to respond to clinical
intervention.
Regarding cardiovascular risk assessment, there are some appli-
cable tools, as the determination of C-reactive protein, proinﬂamma-
tory cytokines, FRS and also computed tomography-coronary artery
calcium score. Some of them are employed to evaluate HCV-related
disease progression. In Table 2,the comparison between the present
and previous published studies on cardiovascular risk assessment
tools in HCV patients is shown.
In the current study, we observed higher levels of proinﬂamma-
tory cytokines (IL-6 and TNF-α) in HCV patients compared to controls.
Besides, we described by the ﬁrst time that the relation of
proinﬂammatory/anti-inﬂammatory TNF-α/IL10 and IL-6/IL10 were
higher in HCV patients. These ﬁndings are very important because
there are some studies demonstrating that most liver-inﬁltrating T
cells in chronic hepatitis C are type 1-like cytokines (TH1), such as
IL-1b, IL-2, IL-6, IL-8, TNF-α, and IFN-γ are upregulated in chronic HCV
[25]. However, few studies have been drawn to the role of anti-
inﬂammatory cytokine levels. Interleukin 10 (IL-10) is a potent anti-
inﬂammatory Th2 cytokine that down-regulates the expression of
major histocompatibility complex (MHC) class I and class II
molecules, as well as the production of Th1 cytokines [26–31]. How
proinﬂammatory/anti-inﬂammatory cytokines relations could inter-
fere in the pathogenesis of atherosclerosis in Chronic HCV infection is
very intriguing and unclear. We just hypothesized according to our
results that when these relations (TNF-α/IL10 and IL-6/IL10) were
higher in HCV patients the cardiovascular risk could be increased as
measured by FRS. In this setting, a recent epidemiologic study showed
that HCV-seropositive blood donors had higher rates of cardiovascular
mortality compared to uninfected donors and the altered cytokine
proﬁles observed in the setting of chronic HCV could potentially lead
to adverse cardiovascular outcomes [32,33].
Another important factor related to the cytokine proﬁle that could
contribute to a increased cardiovascular risk in HCV-infected patientsHCV P=0.002 
patients with hepatitis C (HCV).
P<0.0001Control HCV
IL
-6
 (p
g/m
l) 
Groups 
100,00
80,00
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20,00
Fig. 2. Levels of IL-6 in controls and patients with hepatitis C (HCV).
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chronic liver diseases, mainly due the association with activation of
TNF-α system and high IL-6 levels [34]. Lecube et al. demonstrated
that proinﬂammatory cytokines in HCV positive patients with chronic
hepatitis without diabetes and without advanced liver ﬁbrosis haveROC of Data 1:ROC curve
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Fig. 3. ROC curve of pro-inﬂammatory/anti-inﬂammatory indexes in patients with hepati
S = sensibility; E = speciﬁcity.increased levels of sTNFR1, sTNTR2 and TNF-α and these cytokines
have relationship with HOMA-IR suggesting that is a mechanism by
which HCV-infected patients are more prone to develop type 2
diabetes than patients with other chronic liver diseases [34]. The
relation between inﬂammation and IR in the pathogenesis of type 2ROC of Data 1:ROC curve
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tis C in comparison to controls. AUC = area under curve. IC = interval of conﬁdence;
Table 2
Factors related to the assessment of cardiovascular risk and its application in
populations of HCV infected patients. Comparison between the present study and
others previously published.
Variable Cardiovascular risk* Disease progression Present study**
Evaluated Result Evaluated Result Evaluated Result
CRP Yes Increased No NA No NA
IL-6 No NA Yes Increased Yes Increased
TNFα Yes Increased No NA Yes Increased
Pro/Anti No NA Yes Increased Yes Increased
FRS No NA No NA Yes Increased
Where: * non-selected HCV population (naïve and non-naïve, cirrhotics and non-
cirrhotics, obese and non-obese, diabetics and non-diabetics); ** selected HCV patients;
Evaluated means that the variable was studied in order to determine a deﬁnite endpoint
(cardiovascular risk or disease progression); Result means if the variable was related to
the endpoint studied; the present study endpoint was cardiovascular risk; CRP=C-
reactive protein; Pro/Anti=Pro/Anti-antiinﬂammatory rates; FRS=Framingham risk
score.
225C.P.M.S. Oliveira et al. / International Journal of Cardiology 164 (2013) 221–226DM and HCV had been suggested in some years ago [35]. The
mechanisms by which HCV impairs insulin sensitivity include
increased TNF-α and IL-6 production, over-expression of suppressor
of cytokines signal 3 (SOCS-3), as they interfere with the intracellular
signalling pathway of insulin [36]. Our study didn´t show this
association among IL-6 levels and IR.
Recently, Milner et al. [37] demonstrated that the HCV-induced IR
is mainly related to the muscle; it is also independent of increased
hepatic lipid (in genotype 3). Moreover, peripheral IR in hepatitis C
was unusually associated with subcutaneous fat, suggesting a possible
interplay between the virus and the adipocyte, which will need to be
further examined [37].
Our ﬁndings are consistent with other studies ﬁnding low
circulating cholesterol and LDL levels in patients with chronic HCV
infection. However, when considering the FRS, the overall percentage
of HCV patients with intermediate or high 10-yr likelihood for
development of CHD was 1.5-fold increased compared with the
general population. In fact, similar results have been described by
Corey at al [18] who demonstrated that the serum lipids are low
because lipids play a role in HCV virion circulation and hepatocyte
entry. Besides, these authors observed that the hypolipidemia
resolves with successful HCV treatment but persists in nonresponders.
A signiﬁcant proportion of successfully treated patients experience
LDL and cholesterol rebound to levels associated with increased
coronary disease risk. This intriguing paradox between lower serum
lipids and FRS, associated with higher inﬂammatory and pro-
antiinﬂammatory rates of cytokines in our study, could suggest that
chronic inﬂammation in HCV infection leads to modulation of
cytokines Th1/Th2 such as TNF-α and IL-6 increasing the systemic
inﬂammatory cascade without increasing the lipid levels, however
predisposing to atherosclerosis and cardiovascular risk independently
of serum lipids levels. Ruan et al. [38] demonstrated that inﬂamma-
tory stress changes the phenotype of LDLr regulation from sensitive to
resistant for cholesterol-mediated downregulation An increased
threshold for LDL uptake in liver and peripheral cells may lower
plasma cholesterol. This could be a mechanism for the paradoxical
association of low cholesterol with cardiovascular disease in some
patients that have chronic inﬂammation [38]. Thus, may be that
long-term chronic inﬂammation disrupts the sensitivity of feedback
regulation in peripheral cells, therefore, LDL cholesterol is not only
transported to the liver, but also to the peripheral tissues with
impaired cholesterol efﬂux under inﬂammatory stress which cause
excess cholesterol accumulation, foam cell formation, and low LDL
cholesterol concentration [39]. Interestingly, Chen et al. [39] demon-
strated that IL-1β causes statin resistance in both hepatic cell line
(HepG2) and human kidney mesangial cells (HMCs) under inﬂam-
matory conditions [38]; therefore, higher concentrations of statinmaybe required to achieve the same degree of biological effect in each cell
type. It may also explain why statins, which provide cardiovascular
protection in the general population, do not reduce cardiovascular
mortality in dialysis patients with DM in chronic inﬂammatory states
[40].
In summary, even in patients previously expected to have low-risk
to cardiovascular diseases, HCV seems to increase that risk, as the
presence of the infection was related to higher FRS as well as higher
pro-antiinﬂammatory cytokine proﬁle.
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